Skip to main content
. 2020 Feb 3;86(5):991–998. doi: 10.1111/bcp.14211

Table 3.

Literature data on azacitidine (AZA) involvement in cardiac events

Clinical trial AZA protocol Event Frequency (n)
AZA in combination with thalidomide in MDS17 75 mg/m2 for 5 days every 28 days Pericarditis atrial fibrillation 2% (1) 5% (2)
Phase II, 3 alternative dosing schedules of AZA in MDS8 75 or 50 mg/m2 with various time intervals Congestive heart failure 3% (5)
Phase II, addition of AZA to standard chemotherapy in older patients with AML14 75 mg/m2 for 5 days every 28 days Recruitment halted due to increased rate of cardiac toxicity in the experimental arm No details
Phase I, lenalidomide and AZA in high‐risk MDS18 75 or 50 mg/m2 with various time intervals Atrial fibrillation grade 3 or 4 3% (1)
Phase II, AZA and lenalidomide in with higher‐risk MDS7 75 mg/m2 for 5 days every 28 days Congestive heart failure, arrhythmia, vasovagal episode 11% (4)
Phase II, prophylactic AZA and donor lymphocyte infusion following allogenic hematopoietic stem cell transplantation for high‐risk AML and MDS9 32 mg/m2 for 5 days every 28 days Sudden death due to heart failure 3% (1)

MDS, myelodysplastic syndrome; AML, acute myeloid leukaemia